• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hemoglobin A1c Monitoring - Global Strategic Business Report Product Image

Hemoglobin A1c Monitoring - Global Strategic Business Report

  • ID: 2785211
  • February 2014
  • Region: Global
  • 229 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for Hemoglobin A1c Monitoring in US$ Million by the following Test Types: HbA1c Laboratory Testing, and HbA1c Point of Care Testing.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 27 companies including many key and niche players such as -

- Abbott Laboratories
- ARKRAY, Inc.
- Axis-Shield plc
- Bayer Healthcare Diabetes Care
- Beckman Coulter, Inc.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study
HbA1c Laboratory Testing
HbA1c Point of Care Testing

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
A Quick Primer
Growth Stimulants in a Nutshell
Major Concerns
Increasing Diabetes Prevalence
A Major Growth Propeller
Table 1: Worldwide Prevalence of Diabetes Mellitus by Region (2013 & 2035) (includes corresponding Graph/Chart)
Table 2: Incidence of Diabetes in Select Countries (2013 & 2035) (includes corresponding Graph/Chart)
Table 3: World's Health Expenditure on Diabetes by Region (2013E): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 Years to Treat Diabetes and Manage Associated Complications (includes corresponding Graph/Chart)
Table 4: Global Expenditure on Diabetes Treatment (2012): Spending (in US$ Billion) by Income Strata (includes corresponding Graph/Chart)
Rapidly Aging Demographics and Growing Incidence of Diabetes: Major Driving Factors
Table 5: Elderly Population (60+ Years) as a Percentage of Total Population (2012 & 2050) (includes corresponding Graph/Chart)
Table 6: Global Aging Population (60+) and their Proportion of Total Population (2012) (includes corresponding Graph/Chart)
Increasing Obesity Levels Underpins Market Growth
Table 7: Global Obesity Population (2013) (includes corresponding Graph/Chart)
Table 8: Prevalence of Adult Obesity in Select Countries (2012) (includes corresponding Graph/Chart)
Developing Nations: Future Growth Opportunities
Increase in Healthcare Spending in Emerging Markets
Table 9: Healthcare Spending as % of GDP in Select Countries (2011) (includes corresponding Graph/Chart)
Manufacturers Focus on Offering Products for Developing Markets
Near Patient Testing Gaining Ground
Regular HbA1c Test Keeps Heart Risk at Bay
Diabetes Diagnosis: Opportunities for HbA1c Testing
Is HbA1c Test Right in Being Recommended for Diagnostic Purposes?
Glycosylated Hemoglobin Tests: Paving Way for Early Stage Diabetes Diagnosis
Technology Developments Revolutionize Diagnostics in Diabetes Care
POC Testing: Positive Opportunities in Store
Complex Competitive Environment Prevails in POC Diagnostics Market
POC HbA1c Tests: Significant Advantages over Lab Tests
Major Testing Methods in POC HbA1c Tests
Immunoassays
Boronate Affinity Chromatography
Micro-Optical Detection Methods
Select HbA1c POC Tests in the Market
A Comparison
Home Monitoring: Laced with Accuracy Concerns
Glycated Albumin
A Potential Threat to HbA1c?
Higher Levels of Glycosylated Hemoglobin Increases Risk of Death
Non-Invasive Glucose Meters and CBGM Devices Threatens HbA1c Market
ESC and ADA Release Revised Guidelines for HbA1c Testing
Competitive Landscape
Table 10: Leading Players in the Global HbA1c Reagent Market (2012): Percentage Breakdown of Revenues for Bayer Diabetes Care, Siemens, and Others (includes corresponding Graph/Chart)

2. DIABETES A BRIEF PROFILE OF THE DISEASE

What Causes Diabetes?
Types of Diabetes
Major Types of Diabetes
Likely Complications
Nephropathy (Kidney Disease)
Diabetic Neuropathy (Nerve Damage)
Retinopathy (Damage to the Eye and Blindness)
Poor Healing of Infections and Wounds
Impotence in Men
Periodontal Disease
Cardiovascular Disease
Interpreting the A1c Range
Blood Glucose Level Guidelines in the US
A Glance at Key Diabetes Statistics
Table 11: World Diabetes and Population Statistics (2013 & 2035) (includes corresponding Graph/Chart)
Table 12: World Diabetes and Population Statistics (in Million) by Region (2013E & 2035P)
Breakdown by Africa, Middle East and North Africa, Europe, North America and Caribbean Region, South and Central America, South East Asia, and Western Pacific (includes corresponding Graph/Chart)
Prevalence of Diabetes in Various Parts of the World
Table 13: Global Prevalence of Diabetes Mellitus (in Million) by Gender (2013E)
Breakdown by Region for Africa, Middle East and North Africa, Europe, North America and Caribbean Region, South and Central America, South East Asia, and Western Pacific (includes corresponding Graph/Chart)
Table 14: Global Prevalence of Diabetes Mellitus (in Million) by Age Group (2013)
Breakdown by Region for Africa, Middle East and North Africa, Europe, North America and Caribbean Region, South and Central America, South East Asia, and Western Pacific Region (includes corresponding Graph/Chart)
Table 15: World Diabetes Market (2013 & 2035): Top 10 Regions with Highest Number of People Diagnosed with Diabetes (in Million) in Age Group 20-79 years (includes corresponding Graph/Chart)
Table 16: Proportion of Undiagnosed Diabetes Cases (20-79 Years) by Region (2013E) (includes corresponding Graph/Chart)
Table 17: Proportion of Deaths on Account of Diabetes in People Aged Less than 60 Years by Region (2013E) (includes corresponding Graph/Chart)
Therapeutic Options for Diabetes
Oral Medications for Type 2 Diabetes
Side Effects of Insulin Therapy
Maintaining A1c Test Result Below 7%
Common Diabetes Management Practices

3. PRODUCT OVERVIEW

Hemoglobin
A Brief
Hemoglobin A1c- Description
HbA1c Monitoring
What is A1c?
1. HbA1c Laboratory Testing
2. HbA1c Point of Care Testing & Self-Monitoring
Hemoglobin A1c (HbA1c) Test
Interpreting HbA1c Test Readings
Result of Hemoglobin A1c Test
Clinical Use of A1c Testing
Advantages of A1c Assessment & Interpretation
Risks Associated with HbA1c Testing
Methods of Measurement for Glycohemoglobin
Why Opt for HbA1c Testing?
The Diabetes Control & Complications Trial (DCCT)
The Kumamoto and UK Prospective Studies
Glycemia Tests Used in Monitoring Diabetes
Urine Glucose Testing
Glycated Protein Testing
Table 18: Relation Between A1c Level and Mean Plasma Glucose Levels
HbA1c Test Types
HbA1c Laboratory Testing
Analytical Techniques Used for Quantifying HbA1c in Labs
Standardization of HbA1c Results
Table 19: CAP Accuracy Grading for HbA1c Measurements ( 2007-2013)
Select Laboratory-based HbA1c Testing Products/Analyzers
HbA1c Point of Care Testing & Self-Monitoring
Select Point of Care HbA1c Testing Products/ Analyzers
Standardization of Glycated Hemoglobin Testing
NGSP Standardization of HbA1c
IFCC Standardization of HbA1c
HbA1c Reporting
A1c (%) and Corresponding eAG Number (in mg/dl or mmol/l)

4. PRODUCT APPROVALS/INTRODUCTIONS

Piramal Enterprises Unveils Instant QDx Range of Diagnostic Devices
Roche Launches Cobas B 101 System for Managing Metabolic Syndrome
Convergys® Launches POC HbA1c Analyzer
Sanofi Showcases MyStar Extra® Self-Monitoring Meter
Roche Unveils New HbA1c Test for Diagnosis of Diabetes
Erba Mannheim Unveils New Hb-Vario HPLC System
EKF Launches Quo-Test POC HbA1c Analyzer
Roche Receives FDA Approval for COBAS INTEGRA 800 Tina-quant HbA1cDx Assay
Beckman Coulter Gets FDA Clearance for Hemoglobin A1c Assay Tests
Pointe Scientific Launches A1c Automated Assay for Beckman DXC 600 Analyser
Dynacare Upgrades Hematology Software in Hemoglobin A1C Testing
Tosoh Bioscience Introduces GX Glycohemoglobin Analyzer
Siemens Secures CE Marking for DCA HbA1c Test Kit
EKF Obtains CE Mark for Quo-Lab POC HbA1c Analyser
Streck Launches A1c-Cellular Linearity Verification Material
Abbott Obtains CE Marking for ARCHITECT HbA1c (IA) Fully Automated Assay
Tosoh Bioscience Develops ST AIA-PACK HbA1c Assay
Trinity Obtains FDA Approval for Premier Hb9210 HbA1c Device
Siemens Launches Fortified Version of DCA Vantage Analyzer
Tosoh Launches New Assay on its AIA-600II and AIA-360 Analyzers

5. RECENT INDUSTRY ACTIVITY

Quest Diagnostics Sells HemoCue Business to Radiometer
Techne Takes Over Bionostics
Express Diagnostics Takes Over Eveia Medical
BioHermes Enters into Agreement to Acquire HbA1c Technology from Scripps Laboratories
HemoCue America Inks 5-Year Agreement with ARC
Bio-Rad Laboratories Inks Development Agreement with Inpeco
Danaher Acquires Beckman Coulter
Alere Purchases Additional Shares of Axis-Shield
EKF Diagnostics Inaugurates New Manufacturing Plant in the UK
MinuteClinic Signs Agreement with Axis-Shield
Trinity Inks Distribution Agreement with Menarini for Premier Hb9210

6. FOCUS ON SELECT PLAYERS

Abbott Laboratories (US)
ARKRAY, Inc. (Japan)
Axis-Shield plc (UK)
Bayer Healthcare Diabetes Care (US)
Beckman Coulter, Inc. (US)
Bio-Rad Laboratories Inc (US)
Diazyme Laboratories Inc. (US)
EKF Diagnostics Holdings Plc (UK)
HEMOCUE® AB (Sweden)
Infopia Co. Ltd. (South Korea)
Menarini Diagnostics Ltd. (UK)
Roche Diagnostics (Switzerland)
Siemens Healthcare Diagnostics (Germany)
Tosoh Bioscience, Inc (US)
Trinity Biotech plc (Ireland)

7. GLOBAL MARKET PERSPECTIVE

Table 20: World Recent Past, Current & Future Analysis for HbA1c Monitoring by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 21: World Historic Review for HbA1c Monitoring by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 22: World 15-Year Perspective for HbA1c Monitoring by Geographic Region
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 23: World Recent Past, Current & Future Analysis for Laboratory-based HbA1c Monitoring by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 24: World Historic Review for Laboratory-based HbA1c Monitoring by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 25: World 15-Year Perspective for Laboratory- based HbA1c Monitoring by Geographic Region
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 26: World Recent Past, Current & Future Analysis for Point-of-Care (POC)-based HbA1c Monitoring by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 27: World Historic Review for Point-of-Care (POC)-based HbA1c Monitoring by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 28: World 15-Year Perspective for Point-of-Care (POC)-based HbA1c Monitoring by Geographic Region
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A.Market Analysis
Outlook
HbA1c
Increasingly Moving into Physician’s Office
HbA1c Testing for Diabetes Detection Gains Support
ADA Recommends HbA1c Test for Diabetes Diagnosis
ADA Recommends New Guidelines for HbA1c Testing for Certain Patients
Rising Inclination towards CLIA-Waived Tests
Need for Further Stringency in Requirements Arises
Healthcare Reform Legislation: Impact on Diabetes Diagnostics
US Near Patient HbA1c Testing
A Highly Consolidated Market
Table 29: Leading Players in the US Near Patient HbA1c Testing Market (2013): Percentage Share Breakdown of Revenues for Siemens, Axis-Shield, and Others (includes corresponding Graph/Chart)
Diabetes Statistics in North America and Caribbean Region
Table 30: North American and Caribbean Regional Population and Diabetes Prevalence Statistics (2013E)
Top Regions with High Prevalence of Diabetes by Age Group and Gender (includes corresponding Graph/Chart)
Table 31: Diabetes and Population Statistics in North America and Caribbean Region (2013 & 2035) (includes corresponding Graph/Chart)
Diabetes Statistics in the US
An Overview
Age Factor
Table 32: Number of Diabetics by Gender in the US (2013E) (in ‘000s) (includes corresponding Graph/Chart)
Table 33: Number of Diabetics in the US by Age Group (2013E) (in ‘000s) (includes corresponding Graph/Chart)
Prevalence by Race/Ethnicity
Table 34: US Market for Diabetes (2012): Percentage Breakdown of Prevalence by Race/Ethnicity
Non-Hispanic Blacks and Non-Hispanic Whites (includes corresponding Graph/Chart)
Mean HbA1c Scores at National Level
Economic Burden of Diabetes in the US
Table 35: Direct Medical Expenditure on Diabetes Management in the US (2012): Percentage Share Breakdown of Costs Incurred by Component (includes corresponding Graph/Chart)
Table 36: Indirect Costs of Diabetes in the US (2012): Percentage Share Breakdown by Component (includes corresponding Graph/Chart)
Product Approvals/Launches
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 37: US Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 38: US Historic Review for HbA1c Monitoring by Segment- Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011(includes corresponding Graph/Chart)
Table 39: US 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

2. CANADA

A.Market Analysis
Outlook
Diabetes Statistics in Canada
Table 40: Adult Diabetes Population by Gender in Canada (2013) (In ‘000s) (includes corresponding Graph/Chart)
Table 41: Adult Diabetes Population by Age Group in Canada (2013) (In ‘000s) (includes corresponding Graph/Chart)
B.Market Analytics
Table 42: Canadian Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 43: Canadian Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 44: Canadian 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

3. JAPAN

A.Market Analysis
Outlook
ARKRAY, Inc.
A Major Player
B.Market Analytics
Table 45: Japanese Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 46: Japanese Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 47: Japanese 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4. EUROPE

A.Market Analysis
Outlook
Positive Outlook for Diabetes Diagnostics Market in Europe
Proven Efficacy and Benefits of POCT HbA1C Tests Spur Adoption
Competitive Environment
Table 48: Leading Players in the European Point-of-Care HbA1c Tests Market (2011): Percentage Share Breakdown of Revenues for Axis-Shield, Hemocue, Siemens Healthcare Diagnostics, and Others (includes corresponding Graph/Chart)
A Glance at Key Diabetes Statistics in Europe
Table 49: Diabetes and Population Statistics in Europe (2013 & 2035) (includes corresponding Graph/Chart)
Table 50: European Population and Diabetes Prevalence Statistics (2013E)
Select Regions with High Prevalence of Diabetes for Age Groups (20-39, 40-59, and 60-79) and Gender (includes corresponding Graph/Chart)
B.Market Analytics
Table 51: European Recent Past, Current & Future Analysis for HbA1c Monitoring by Geographic Region
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 52: European Historic Review for HbA1c Monitoring by Geographic Region
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 53: European Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 54: European Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 55: European 15-Year Perspective for HbA1c Monitoring by Geographic Region
Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 56: European 15-Year Perspective for HbA1c Monitoring by Segment -Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4a. FRANCE
Market Analysis
Table 57: French Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 58: French Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 59: French 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4b. GERMANY
A.Market Analysis
Outlook
Product Approvals/Introductions
Siemens Healthcare Diagnostics
A Key Player
B.Market Analytics
Table 60: German Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 61: German Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 62: German 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 63: Italian Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 64: Italian Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 65: Italian 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A.Market Analysis
Outlook
Diabetes Statistics & Management
An Insight
Rising Obesity Cases
Increased Risk of Diabetes
Type 1 Diabetes in Children
Table 66: Number of Type 1 Diabetics Per 100,000 Children in Select Countries (2011) (includes corresponding Graph/Chart)
NHS England Launches Action for Diabetes Plan
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 67: UK Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 68: UK Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 69: UK 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4e. SPAIN
A.Market Analysis
Outlook
Product Launch
B.Market Analytics
Table 70: Spanish Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 71: Spanish Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 72: Spanish 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4f. RUSSIA
Market Analysis
Table 73: Russian Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 74: Russian Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 75: Russian 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4g. REST OF EUROPE
A.Market Analysis
Outlook
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 76: Rest of Europe Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 77: Rest of Europe Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 78: Rest of Europe 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A.Market Analysis
Outlook
Diabetes Statistics
An Overview
Table 79: Diabetes and Population Statistics in Western Pacific (2013 & 2035) (includes corresponding Graph/Chart)
Table 80: Western Pacific Population and Diabetes Prevalence Statistics (2013E)
Select Regions with High Prevalence of Diabetes for Various Age Groups (20-39, 40-59, and 60-79) and Gender (includes corresponding Graph/Chart)
Table 81: Diabetes and Population Statistics in South East Asia (2013 & 2035) (includes corresponding Graph/Chart)
Table 82: South East Asian Population and Diabetes Prevalence Statistics (2013 Estimates)
Select Regions with High Prevalence of Diabetes for Various Age Groups (20-39, 40-59, and 60-79) and Gender (includes corresponding Graph/Chart)
B.Market Analytics
Table 83: Asia-Pacific Recent Past, Current & Future Analysis for HbA1c Monitoring by Geographic Region
China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 84: Asia-Pacific Historic Review for HbA1c Monitoring by Geographic Region
China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 85: Asia-Pacific 15-Year Perspective for HbA1c Monitoring by Geographic Region
Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 86: Asia-Pacific Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 87: Asia-Pacific Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 88: Asia-Pacific 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
5a. CHINA
A.Market Analysis
Outlook
Increasing Diabetes Incidence Spurs Growth in Diabetes Diagnostics Market
Strategic Corporate Development
B.Market Analytics
Table 89: Chinese Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 90: Chinese Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 91: Chinese 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
5b. INDIA
A.Market Analysis
Outlook
HbA1c Testing on Growth Spree
Growth Stimulants & Challenges in a Nut Shell
Rising Diabetes Cases
Opportunities for HbA1c Monitoring Market
Product Launch
B.Market Analytics
Table 92: Indian Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 93: Indian Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 94: Indian 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
5c. REST OF ASIA-PACIFIC
A.Market Analysis
Outlook
Diabetes Statistics in Australia
Table 95: Diabetes Population Breakdown by Age Group in Australia (2011-12) (includes corresponding Graph/Chart)
Infopia Co. Ltd. (South Korea)
A Major Player
B.Market Analytics
Table 96: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 97: Rest of Asia-Pacific Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 98: Rest of Asia-Pacific 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

A.Market Analysis
Outlook
Diabetes in Latin America
A Glance at Key Statistics
Table 99: Diabetes and Population Statistics in Central and South America (2013 & 2035) (includes corresponding Graph/Chart)
Table 100: Central and South American Population and Diabetes Prevalence Statistics (2013 Estimates)
Select Regions with High Prevalence of Diabetes for Various Age Groups (20-39, 40-59, and 60-79) and Gender (includes corresponding Graph/Chart)
B.Market Analytics
Table 101: Latin American Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 102: Latin American Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 103: Latin American 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

A.Market Analysis
Outlook
Diabetes Statistics in Africa and the Middle East
Table 104: African Diabetes and Population Statistics (2013 & 2035) (includes corresponding Graph/Chart)
Table 105: African Population and Diabetes Prevalence Statistics (2013)
Select Regions with High Prevalence of Diabetes for Various Age Groups (20-39, 40-59, and 60-79) and Gender (includes corresponding Graph/Chart)
Table 106: Diabetes and Population Statistics in Middle East and North Africa (2013 & 2035) (includes corresponding Graph/Chart)
Table 107: Middle East and North African Population and Diabetes Prevalence Statistics (2013 Estimates)
Select Regions with High Prevalence of Diabetes for Various Age Groups (20-39, 40-59, and 60-79) and Gender (includes corresponding Graph/Chart)
B.Market Analytics
Table 108: Rest of World Recent Past, Current & Future Analysis for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2012 through 2020 (includes corresponding Graph/Chart)
Table 109: Rest of World Historic Review for HbA1c Monitoring by Segment
Laboratory Testing and Point of Care Testing Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2011 (includes corresponding Graph/Chart)
Table 110: Rest of World 15-Year Perspective for HbA1c Monitoring by Segment
Percentage Breakdown of Dollar Sales for Laboratory Testing and Point of Care Testing Markets for years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 27 (including Divisions/Subsidiaries 35)
The United States (14)
Canada (1)
Japan (3)
Europe (14)
Germany (3)
The United Kingdom (5)
Italy (1)
Rest of Europe (5)
Asia-Pacific (Excluding Japan) (3)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos